Understanding METTL3 in Aggressive Chronic Lymphocytic Leukemia
Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia
This research explores how a protein called METTL3 contributes to aggressive forms of chronic lymphocytic leukemia (CLL) to find new ways to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11127460 on NIH RePORTER |
What this research studies
Aggressive chronic lymphocytic leukemia (CLL) can be very difficult to treat, even with current therapies. Our team has found that a protein called METTL3 might play a key role in making CLL more aggressive by affecting how RNA works in cancer cells. We believe that by understanding how METTL3 drives CLL, we can develop new treatments. This work will help us learn more about this protein's role and explore potential new medicines that target it.
Who could benefit from this research
Good fit: This research focuses on understanding aggressive chronic lymphocytic leukemia, which could eventually benefit patients diagnosed with this specific type of blood cancer.
Not a fit: Patients without chronic lymphocytic leukemia or those with less aggressive forms of the disease may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new, more effective treatments for patients with aggressive chronic lymphocytic leukemia.
How similar studies have performed: Other studies have shown promising results with drugs that target METTL3 in different blood cancers, suggesting this approach has potential.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Wang, Lili — Beckman Research Institute/city of Hope
- Study coordinator: Wang, Lili
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.